GSM gold starGSM Global
中文版 · Chinese

EMA's CHMP Meeting of November 9-12: Seven New Medicines Recommended for Approval, With Indication Extensions Recommended for 11 More

Monday, November 16, 2026 · Health · GSM News

The European Medicines Agency (EMA) has published the highlights of its Committee for Medicinal Products for Human Use (CHMP) meeting of November 9-12, 2026, at which the committee recommended seven new medicines for approval. The EMA is headquartered in Amsterdam, the Netherlands, and CHMP opinions are sent to the European Commission for a final decision.

Among the new medicines, the committee recommended granting a marketing authorisation for Aumseqa (aumolertinib) for non-small cell lung cancer, and for Baxfendy (baxdrostat) for insufficiently controlled hypertension. Zybrivo (sintilimab) received a positive opinion for non-squamous non-small cell lung cancer in adults. Two insulin aspart biosimilars, Garzulys and Donrafylix, received positive opinions for diabetes mellitus in adults, adolescents and children aged 1 year and above, as did two generics, Fondaparinux sodium Evumed and Ruxolitinib Krka.

The committee also recommended extensions of therapeutic indication for 11 medicines, including extending Gazyvaro (obinutuzumab) to adults with moderate-to-severe active systemic lupus erythematosus whose disease is not adequately controlled by standard treatment, and extending Isturisa (osilodrostat) to adolescents and children aged 6 years and older with endogenous Cushing's syndrome.

Following re-examination, the committee confirmed its recommendation to refuse marketing authorisation for two medicines: KemSu (sufentanil/ketamine) for acute pain in children and adolescents, and Meplyffa (arimoclomol citrate) for Niemann-Pick disease type C. Applications for two other medicines were withdrawn. The committee also adopted a direct healthcare professional communication on the potential effect of Mounjaro (tirzepatide) on the reliability of oral contraceptives, advising women who can become pregnant to add a barrier method for four weeks after starting tirzepatide and after each dose increase, or to switch to a non-oral method.

Published by GSM · USA (original Chinese edition)

Photo: Wikimedia Commons, File:2020 European Medicines Agency.jpg — Author: Ceescamel. Licensing: CC BY-SA 4.0.

Latest in Health